We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Luke Miles

Luke A Miles MD

Dr. Luke Miles has led a National Health and Medical Research Council of Australia -funded laboratory since 2008 at St. Vincent's Institute of Medical Research, Melbourne, Australia. Dr. Miles is also an Honorary Fellow of the University of Melbourne. His lab is dedicated to understanding the function and processing of the amyloid precursor protein (APP), and mechanisms of promoting clearance of pathological species that drive Alzheimer's disease (AD). This work relies on biophysical methods of investigation including solution state NMR, 3D-structure determination by X-ray crystallography and small angle X-ray scattering, kinetic measurements, circular dichroism and fluorimetry. Such data informs experiments in vivo supported by collaboration with neuroscientists at the Florey Institute of Neuroscience and Mental Health in Melbourne. Dr. Miles gained expertise in recombinant protein expression, purification and biophysical analysis as a postdoctoral fellow at the Walter and Eliza Hall Institute of Medical Research and as a Japan Society Promotion of Science Fellow at Tokyo Metropolitan University. Dr. Miles solved one of the first anti-amyloid-antibody atomic structures reported in 2008 and has since solved more than half a dozen AD-related antibody complex structures including the most developed immunotherapy candidate, bapineuzumab. These structures form the templates for an antibody engineering program to develop immunotherapies with high affinity and exquisite specificity for different structures of both the amyloid beta peptide and the downstream related biomarker, hyperphosphorylated Tau protein. This work has attracted competitive funding from the Mason Foundation, the Bethlehem Griffith Research Foundation and the Wicking Trust.

Recent Contributions to PracticeUpdate:

  1. Missing the Target With Anti-Aβ Antibodies